Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

920
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
920
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

672
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
672
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.1K
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

1.1K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.1K
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

575
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
575
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

347
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
347

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Natural History of C3 Glomerulopathy and Immune Complex-Associated Membranoproliferative Glomerulonephritis in Children.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Blood Pressure Control in Adolescents With CKD and Risk of Kidney Failure in Young Adulthood.

Kidney medicine·2026
Same author

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

Advances in therapy·2026
Same author

Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Contemporary Treatment Responses of Recurrent Focal Segmental Glomerulosclerosis or Steroid Resistant Nephrotic Syndrome in Children after Kidney Transplantation: Phase 2 of a Multicenter Electronic Health Record Data Analysis.

Research square·2026
Same author

Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease.

JAMA pediatrics·2026

Related Experiment Video

Updated: Feb 10, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.2K

Atypical Hemolytic Uremic Syndrome.

Bradley P Dixon1, Ralph A Gruppo2

  • 1Renal Section, Department of Pediatrics, University of Colorado School of Medicine, 13123 East 16th Avenue, Aurora, CO 80045, USA.

Pediatric Clinics of North America
|May 28, 2018
PubMed
Summary

Atypical hemolytic uremic syndrome (aHUS) is a severe condition caused by uncontrolled complement activation. Eculizumab offers a recommended front-line therapy to prevent organ damage in aHUS patients.

Keywords:
Atypical hemolytic uremic syndromeComplement activationEculizumabThrombotic microangiopathies

More Related Videos

Clinical Examination Protocol to Detect Atypical and Classical Scrapie in Sheep
13:42

Clinical Examination Protocol to Detect Atypical and Classical Scrapie in Sheep

Published on: January 19, 2014

14.1K
EEG Mu Rhythm in Typical and Atypical Development
11:50

EEG Mu Rhythm in Typical and Atypical Development

Published on: April 9, 2014

26.6K

Related Experiment Videos

Last Updated: Feb 10, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.2K
Clinical Examination Protocol to Detect Atypical and Classical Scrapie in Sheep
13:42

Clinical Examination Protocol to Detect Atypical and Classical Scrapie in Sheep

Published on: January 19, 2014

14.1K
EEG Mu Rhythm in Typical and Atypical Development
11:50

EEG Mu Rhythm in Typical and Atypical Development

Published on: April 9, 2014

26.6K

Area of Science:

  • Nephrology
  • Immunology
  • Hematology

Background:

  • Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy.
  • It involves unregulated complement activation, leading to poor prognosis with high mortality and end-stage renal disease rates within a year.
  • The disease systemically affects multiple organs, including kidneys, brain, heart, and lungs.

Purpose of the Study:

  • To summarize the pathophysiology and current treatment recommendations for atypical hemolytic uremic syndrome.
  • To highlight the role of complement dysregulation in the disease.
  • To emphasize the efficacy of eculizumab in managing aHUS.

Main Methods:

  • Review of literature on atypical hemolytic uremic syndrome.
  • Analysis of disease characteristics, including thrombotic microangiopathy, hemolysis, thrombocytopenia, and renal impairment.
  • Evaluation of complement system abnormalities in patients.
  • Assessment of treatment outcomes, including plasma therapy and eculizumab.

Main Results:

  • Atypical hemolytic uremic syndrome is characterized by thrombotic microangiopathy and multiorgan involvement.
  • Genetic or acquired complement dysregulation is identified in approximately 70% of patients.
  • Plasma therapy is largely ineffective for treating aHUS.
  • Eculizumab effectively blocks terminal complement activation and prevents organ damage.

Conclusions:

  • Atypical hemolytic uremic syndrome is a severe systemic disease driven by complement dysregulation.
  • Eculizumab represents a crucial front-line therapy for preventing complement-mediated organ damage in aHUS.
  • Early diagnosis and treatment are vital for improving patient outcomes in atypical hemolytic uremic syndrome.